Royalty Pharma Reports 7.9% Revenue Growth to $609.3 Million in Q3 2025

Royalty Pharma plc reported its financial results for the third quarter and the first nine months of 2025, revealing a total income of $609.3 million for the quarter, a 7.9% increase from $564.7 million in the same period last year. For the nine months ended September 30, 2025, total income reached $1.76 billion, up 5.2% from $1.67 billion in 2024. The increase in revenue was primarily driven by a rise in income from financial royalty assets, which amounted to $578.8 million for the quarter, compared to $533.2 million in the prior year, reflecting an 8.6% increase. Year-to-date, income from financial royalty assets totaled $1.67 billion, a 5.1% increase from $1.59 billion in 2024.

The company experienced significant changes in its operating expenses, which totaled $182.1 million for the third quarter, compared to a net income of $(170.4) million in the same quarter of 2024. This shift was largely due to a provision for changes in expected cash flows from financial royalty assets, which recorded an expense of $12.1 million, contrasting sharply with a provision income of $227.6 million in the previous year. General and administrative expenses surged to $118.7 million, up 109.3% from $56.7 million, primarily due to increased share-based compensation expenses following the company's internalization process completed in May 2025.

Strategically, Royalty Pharma completed the internalization of its management structure in May 2025, transitioning from an externally managed entity to an integrated company. This move involved acquiring the equity interests of its former manager, RP Management, for a total transaction value of approximately $1.1 billion, which included cash and newly issued equity interests. The internalization is expected to enhance operational efficiency and align employee incentives with the company's long-term performance.

Operationally, Royalty Pharma's portfolio includes royalties on over 35 marketed therapies and 17 development-stage product candidates. The company reported a strong performance in its cystic fibrosis franchise, with royalties from Vertex's products contributing significantly to revenue. Additionally, the company has made substantial investments in new royalties, totaling $1.7 billion in the first nine months of 2025, which is expected to support future growth. The company also announced a new share repurchase program, authorizing up to $3 billion in repurchases, with approximately $1.2 billion spent in the first nine months of 2025.

Looking ahead, Royalty Pharma anticipates continued growth driven by its diverse portfolio and strategic investments. The company remains focused on leveraging its strong cash flow generation capabilities to fund future acquisitions and support ongoing operational needs. However, management acknowledges that future performance is subject to various risks, including market conditions and the performance of the underlying biopharmaceutical products from which it derives royalties.